RxDoctor Payments Data

Jason Bundy, MD

Interventional Pain Medicine · Wyomissing, PANPI 1164644548

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Abbott at 41.3% of the total. Reporting peaked in 2024 at $2,198 and has fallen 56.0% since, to $968 in 2025.

$7,709in general payments, 2019–2025

Across 266 payments — averaging $28.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$2K
  • Boston Scientific$504
  • Pfizer$254
  • Relievant Medsystems, Inc.$157
  • Collegium Pharmaceutical, Inc.$157
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$7,705100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,709 in reported general payments places this provider in the 75th percentile of 59 interventional pain medicine providers in Pennsylvania.

See all interventional pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$176,728
Medicare patients
416
Services billed
2,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl23$13,088
Buprenorphine13$2,140
Morphine Sulfate ErMorphine Sulfate28$777
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen33$740
Gabapentin38$556
Oxycodone Hcl39$509
Pregabalin37$496
Duloxetine Hcl21$356
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$304
Tramadol Hcl35$163
Cyclobenzaprine Hcl21$149
Acetaminophen-CodeineAcetaminophen With Codeine13$116
Alprazolam69$59

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →